<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39458617</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Development of Targeted Drug Delivery System for the Treatment of SARS-CoV-2 Using Aptamer-Conjugated Gold Nanoparticles.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1288</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16101288</ELocationID><Abstract><AbstractText><b>Background:</b> The SARS-CoV-2 pandemic has highlighted niclosamide (NIC) as a promising treatment for COVID-19. However, its clinical application is limited due to its poor water solubility, resulting in low bioavailability. <b>Methods:</b> To address this issue, we developed a AuNP-HA-NIC system, which combines gold nanoparticles with hyaluronic acid to enhance drug delivery. Our comprehensive characterization of the system revealed that hyaluronic acid with specific molecular weights, particularly those exposed to electron-beam irradiation between 2 and 20 kGy, produced the most stable nanoparticles for efficient drug loading and delivery. <b>Results:</b> Additionally, the AuNP-HA-NIC system exhibits a significant sensitivity to pH changes, which is a critical feature for targeted drug release. Under acidic conditions mimicking the stomach and small intestine, minimal drug release was observed, indicating the effective prevention of premature drug release in the gastrointestinal tract. Furthermore, the integration of a targeting aptamer established specific binding abilities towards the SARS-CoV-2 spike protein, distinguishing it from other coronaviruses. <b>Conclusions:</b> As research progresses, and with further in vivo testing and optimization, the AuNP-HA-NIC-aptamer system holds great promise as a game-changer in the field of antiviral therapeutics, particularly in the battle against COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Junghun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3122-3288</Identifier><AffiliationInfo><Affiliation>Department of Biologics, Gachon University, Incheon 21936, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Hyogu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0409-3331</Identifier><AffiliationInfo><Affiliation>User Convenience Technology R&amp;D Department, Korea Institute of Industrial Technology (KITECH), Ansan 15588, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Gangneung-Wonju National University, Gangneung 25457, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jun Ki</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0001-6405-9923</Identifier><AffiliationInfo><Affiliation>User Convenience Technology R&amp;D Department, Korea Institute of Industrial Technology (KITECH), Ansan 15588, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20018549</GrantID><Agency>MOTIE (Ministry of Trade, Industry and Energy) and KEIT (Korea Planning &amp; Evaluation Institute of Industrial Technology) of Republic of Korea</Agency><Country /></Grant><Grant><GrantID>RS-2024-00400234</GrantID><Agency>Ministry of Trade, Industry and Energy (MOTIE, Korea)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">controlled release</Keyword><Keyword MajorTopicYN="N">drug delivery</Keyword><Keyword MajorTopicYN="N">gold nanoparticle</Keyword><Keyword MajorTopicYN="N">hyaluronic acid</Keyword><Keyword MajorTopicYN="N">niclosamide</Keyword><Keyword MajorTopicYN="N">one-pot synthesis</Keyword><Keyword MajorTopicYN="N">poorly water-soluble drug</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39458617</ArticleId><ArticleId IdType="pmc">PMC11510760</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16101288</ArticleId><ArticleId IdType="pii">pharmaceutics16101288</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mallapaty S., Ruxrungtham K. The pioneer behind southeast Asia’s first mRNA COVID vaccine. Nature. 2021;594:163. doi: 10.1038/d41586-021-01426-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01426-9</ArticleId><ArticleId IdType="pubmed">34040244</ArticleId></ArticleIdList></Reference><Reference><Citation>Padma T.V. How COVID changed schools outreach. Nature. 2021;594:289–291. doi: 10.1038/d41586-021-01517-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01517-7</ArticleId><ArticleId IdType="pubmed">34099915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. Br. Med. J. 2021;375:n2422. doi: 10.1136/bmj.n2422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2422</ArticleId><ArticleId IdType="pubmed">34607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Willyard C. How gut microbes could drive brain disorders. Nature. 2021;590:22–25. doi: 10.1038/d41586-021-00260-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00260-3</ArticleId><ArticleId IdType="pubmed">33536656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad B., Batool M., Ain Q., Kim M.S., Choi S. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. Int. J. Mol. Sci. 2021;22:9124. doi: 10.3390/ijms22179124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179124</ArticleId><ArticleId IdType="pmc">PMC8430524</ArticleId><ArticleId IdType="pubmed">34502033</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu R., Matsuzaki T., Oka R., Sonoyama T., Fukuhara T., Kuwata A., Matsuo Y., Kubota R. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies. J. Clin. Pharmacol. 2023;63:918–927. doi: 10.1002/jcph.2247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2247</ArticleId><ArticleId IdType="pubmed">37043676</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibaldi B.T., Wang K., Robinson M.L., Zeger S.L., Bandeen-Roche K., Wang M.C., Alexander G.C., Gupta A., Bollinger R., Xu Y. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients with COVID-19. JAMA Netw. Open. 2021;4:e213071. doi: 10.1001/jamanetworkopen.2021.3071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.3071</ArticleId><ArticleId IdType="pmc">PMC7991975</ArticleId><ArticleId IdType="pubmed">33760094</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezagholizadeh A., Khiali S., Sarbakhsh P., Entezari-Maleki T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur. J. Pharmacol. 2021;897:173926. doi: 10.1016/j.ejphar.2021.173926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173926</ArticleId><ArticleId IdType="pmc">PMC7859696</ArticleId><ArticleId IdType="pubmed">33549577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan V.C., Muller F.L. Remdesivir for COVID-19: Why Not Dose Higher? Antimicrob. Agents Chemother. 2021;65:e02713-20. doi: 10.1128/AAC.02713-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02713-20</ArticleId><ArticleId IdType="pmc">PMC8097423</ArticleId><ArticleId IdType="pubmed">33558301</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer O. COVID-19: Remdesivir has little or no impact on survival, WHO trial shows. Br. Med. J. 2020;371:m4057. doi: 10.1136/bmj.m4057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4057</ArticleId><ArticleId IdType="pubmed">33077424</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J. Abstract PS16-33: Niclosamide reverses cisplatin resistance by inhibiting Bcl-2 and Stat3 in HER2-positive breast cancer. Cancer Res. 2021;81:PS16–PS33. doi: 10.1158/1538-7445.SABCS20-PS16-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.SABCS20-PS16-33</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauraj Kumar A., Kumar B., Kulshreshtha A., Negi Y.S. Redox-sensitive nanoparticles based on xylan-lipoic acid conjugate for tumor targeted drug delivery of niclosamide in cancer therapy. Carbohydr. Res. 2021;499:108222. doi: 10.1016/j.carres.2020.108222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carres.2020.108222</ArticleId><ArticleId IdType="pubmed">33401229</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Qiu Q., Zeng S., Xiao Y., Shi M., Zou Y., Ye Y., Liang L., Yang X., Xu H. Niclosamide inhibits the inflammatory and angiogenic activation of human umbilical vein endothelial cells. Inflamm. Res. 2015;64:1023–1032. doi: 10.1007/s00011-015-0888-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-015-0888-8</ArticleId><ArticleId IdType="pubmed">26499405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Mook R.A., Premont R.T., Wang J. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018;41:89–96. doi: 10.1016/j.cellsig.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2017.04.001</ArticleId><ArticleId IdType="pmc">PMC5628105</ArticleId><ArticleId IdType="pubmed">28389414</ArticleId></ArticleIdList></Reference><Reference><Citation>Gassen N.C., Niemeyer D., Muth D., Corman V.M., Martinelli S., Gassen A., Hafner K., Papies J., Mösbauer K., Zellner A., et al. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat. Commun. 2019;10:5770. doi: 10.1038/s41467-019-13659-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13659-4</ArticleId><ArticleId IdType="pmc">PMC6920372</ArticleId><ArticleId IdType="pubmed">31852899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.J., Jan J.T., Chen C.M., Hsieh H.P., Hwang D.R., Liu H.W., Liu C.Y., Huang H.W., Chen S.C., Hong C.F., et al. Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide. Antimicrob. Agents Chemother. 2004;48:2693–2696. doi: 10.1128/AAC.48.7.2693-2696.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.7.2693-2696.2004</ArticleId><ArticleId IdType="pmc">PMC434198</ArticleId><ArticleId IdType="pubmed">15215127</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgeit A., McDowell R., Moese S., Meldrum E., Schwendener R., Greber U.F. Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad Antiviral Effects. PLoS Pathog. 2012;8:e1002976. doi: 10.1371/journal.ppat.1002976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002976</ArticleId><ArticleId IdType="pmc">PMC3486884</ArticleId><ArticleId IdType="pubmed">23133371</ArticleId></ArticleIdList></Reference><Reference><Citation>Pindiprolu S.K.S.S., Pindiprolu S.H. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med. Hypotheses. 2020;140:109765. doi: 10.1016/j.mehy.2020.109765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109765</ArticleId><ArticleId IdType="pmc">PMC7195103</ArticleId><ArticleId IdType="pubmed">32361588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa A., Kandeil A., Elshaier Y.A.M.M., Kutkat O., Moatasim Y., Rashad A.A., Shehata M., Gomaa M.R., Mahrous N., Mahmoud S.H., et al. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals. 2020;13:443. doi: 10.3390/ph13120443.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph13120443</ArticleId><ArticleId IdType="pmc">PMC7761982</ArticleId><ArticleId IdType="pubmed">33291642</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S., Shum D., Kim S. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob. Agents Chemother. 2020;64:e00819-20. doi: 10.1128/AAC.00819-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00819-20</ArticleId><ArticleId IdType="pmc">PMC7318052</ArticleId><ArticleId IdType="pubmed">32366720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma R., Ma Z.G., Gao J.L., Tai Y., Li L.J., Zhu H.B., Li L., Dong D.L., Sun Z.J. Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy. J. Biomed. Mater. Res. A. 2020;108:30–38. doi: 10.1002/jbm.a.36788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.36788</ArticleId><ArticleId IdType="pubmed">31433913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S., Hou S., Chen X., Yu D.G., Wang L., Li X., Williams G.R. Energy-Saving Electrospinning with a Concentric Teflon-Core Rod Spinneret to Create Medicated Nanofibers. Polymers. 2020;12:2421. doi: 10.3390/polym12102421.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym12102421</ArticleId><ArticleId IdType="pmc">PMC7589577</ArticleId><ArticleId IdType="pubmed">33092310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotthivirat S., Ramesh R., Wasylaschuk W., Bottone C., Xia B., Stellabott J., McNevin M., Skomski D., Brown C. Effect of TPGS surfactant on dissolution sensitivity of a poorly water-soluble drug using high-shear wet granulation. Powder Technol. 2020;375:302–309. doi: 10.1016/j.powtec.2020.07.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.powtec.2020.07.093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S., Piao H., Rejinold N.S., Jin G., Choi G., Choy J.H. Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment. Polymers. 2021;13:1044. doi: 10.3390/polym13071044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym13071044</ArticleId><ArticleId IdType="pmc">PMC8036780</ArticleId><ArticleId IdType="pubmed">33810527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal N., Garg V., Bhadada S.K., Katare O.P. Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now. Curr. Drug Deliv. 2021;18:289–296. doi: 10.2174/1567201817666200916090710.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567201817666200916090710</ArticleId><ArticleId IdType="pubmed">32938349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.M., Park J.H., Choi Y.J., Oh J.M., Park J. Hyaluronic acid-coated gold nanoparticles as a controlled drug delivery system for poorly water-soluble drugs. RSC Adv. 2023;13:5529–5537. doi: 10.1039/D2RA07276A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2RA07276A</ArticleId><ArticleId IdType="pmc">PMC9926166</ArticleId><ArticleId IdType="pubmed">36798609</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh R., Harwansh R.K., Paul S.D., Shukla R. Controlled release of sulfasalazine loaded amidated pectin microparticles through Eudragit S 100 coated capsule for management of inflammatory bowel disease. J. Drug Deliv. Sci. Technol. 2020;55:101495. doi: 10.1016/j.jddst.2019.101495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2019.101495</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhatre O., Reddy B.P.K., Patnaik C., Chakrabarty S., Ingle A., De A., Srivastava R. pH-responsive delivery of anti-metastatic niclosamide using mussel inspired polydopamine nanoparticles. Int. J. Pharm. 2021;597:120278. doi: 10.1016/j.ijpharm.2021.120278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120278</ArticleId><ArticleId IdType="pubmed">33540007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Zhang X., Zhang T., Wang H., Wu B. Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique. Drug Dev. Ind. Pharm. 2015;41:1416–1424. doi: 10.3109/03639045.2014.954585.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03639045.2014.954585</ArticleId><ArticleId IdType="pubmed">25204767</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand C., Prabhakaran M.P., Beuerman R.W., Lakshminarayanan R., Dwivedi N., Ramakrishna S. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. RSC Adv. 2014;4:32673–32689. doi: 10.1039/C4RA02861A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4RA02861A</ArticleId></ArticleIdList></Reference><Reference><Citation>Salleh A., Naomi R., Utami N.D., Mohammad A.W., Mahmoudi E., Mustafa N., Fauzi M.B. The Potential of Silver Nanoparticles for Antiviral and Antibacterial Applications: A Mechanism of Action. Nanomaterials. 2020;10:1566. doi: 10.3390/nano10081566.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano10081566</ArticleId><ArticleId IdType="pmc">PMC7466543</ArticleId><ArticleId IdType="pubmed">32784939</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk J.S., Xu Q., Kim N., Hanes J., Ensign L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 2016;99 Pt A:28–51. doi: 10.1016/j.addr.2015.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.09.012</ArticleId><ArticleId IdType="pmc">PMC4798869</ArticleId><ArticleId IdType="pubmed">26456916</ArticleId></ArticleIdList></Reference><Reference><Citation>Collnot E.M., Ali H., Lehr C.M. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control Release. 2012;161:235–246. doi: 10.1016/j.jconrel.2012.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2012.01.028</ArticleId><ArticleId IdType="pubmed">22306429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X., Wang X., He M., Wang Y., Lan M., Zhao Y., Gao F. Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy. Int. J. Pharm. 2021;606:120836. doi: 10.1016/j.ijpharm.2021.120836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120836</ArticleId><ArticleId IdType="pubmed">34217824</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>